THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT)

被引:12
|
作者
Sadhu, Archana R. [1 ]
Schwartz, Stanley S. [2 ]
Herman, Mary E. [3 ]
机构
[1] Houston Methodist Hosp Syst, Div Endocrinol Diabet & Metab, Weill Cornell Med Coll, Houston, TX USA
[2] Univ Penn, Main Line Hlth Syst, Philadelphia, PA 19104 USA
[3] Montclair State Univ, Dept Biol & Mol Biol, Montclair, NJ USA
关键词
PANCREATIC BETA-CELLS; INSULIN-SECRETION; RENAL-TRANSPLANTATION; KIDNEY-TRANSPLANT; GROWTH-HORMONE; OPEN-LABEL; TYPE-2; EXENATIDE; GLUCOSE; GLUCAGON;
D O I
10.4158/EP14569.RA
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Owing to advances in transplant science, increasing numbers of patients are receiving solid organ transplantation. New onset diabetes after transplantation (NODAT) frequently develops in transplant patients and requires acute and often ongoing management of hyperglycemia. The metabolic derangements of NODAT are similar to those of classic type 2 diabetes, and treatment has typically followed diabetes standards of care. Best practices for NODAT management remain to be developed. Methods: The mechanistic suitability of incretins to treat NODAT pathogenesis has been hitherto underappreciated. This review details the specific mechanistic value of incretins in patients with immunosuppression-associated hyperglycemia. Results: Corticosteroids have long been known to exert their effects on glucose metabolism by decreasing glucose utilization and enhancing hepatic gluconeogenesis. Corticosteroids also significantly and directly reduce insulin secretion, as do calcineurin inhibitors (CNIs), another commonly used group of immunosuppressive drugs that cause hyperglycemia and NODAT. The ability of incretins to counteract immunosuppressant-induced disruptions in insulin secretion suggest that the insulinotropic, glucagonostatic, and glucose-lowering actions of incretins are well suited to treat immunosuppressant-induced hyperglycemia in NODAT. Additional benefits of incretins include decreased glucagon levels and improved insulin resistance. In the case of glucagon-like peptide-1 (GLP-1) receptor agonists, weight loss is another benefit, countering the weight gain that is a common consequence of both hyperglycemia and transplantation. These benefits make incretins very attractive and deserving of more investigation. Conclusion: Among diabetes treatment options, incretin therapies uniquely counteract immunosuppressant drugs' interference with insulin secretion. We propose an incretin-based treatment paradigm for NODAT management.
引用
收藏
页码:814 / 822
页数:9
相关论文
共 50 条
  • [1] Management of new onset diabetes after transplantation (NODAT) with use of novel algorithm
    Lakhani, Om J.
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2019, 39 (04) : 768 - 773
  • [2] Management of new onset diabetes after transplantation (NODAT) with use of novel algorithm
    Om J. Lakhani
    International Journal of Diabetes in Developing Countries, 2019, 39 : 768 - 773
  • [3] USE OF METFORMIN FOR TREATMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT)
    Tarafdar, S.
    Barbara, J.
    Passaris, G.
    Doogue, M.
    Rowland, A.
    Mcdonald, S. P.
    Crail, S.
    NEPHROLOGY, 2013, 18 : 55 - 55
  • [4] NEW-ONSET DIABETES AFTER Transplantation (NODAT)
    Arnold, L.
    Leikis, M.
    Pidgeon, G.
    Macdonald, A.
    Hay, N.
    Matheson, P.
    NEPHROLOGY, 2012, 17 : 85 - 85
  • [5] New onset diabetes after transplantation (NODAT): an overview
    Pham, Phuong-Thu T.
    Pham, Phuong-Mai T.
    Pham, Son V.
    Pham, Phuong-Anh T.
    Pham, Phuong-Chi T.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2011, 4 : 175 - 186
  • [6] Defining New-Onset Diabetes after Transplantation (NODAT).
    Dhadda, Shobha
    Fitzsimmons, William
    Croy, Richard
    Holman, John
    First, M. Roy
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 243 - 244
  • [7] Impact of New Onset Diabetes after Transplantation (NODAT) on Heart Transplantation Recipients
    Kang, W.
    Wattanakit, K.
    Kim, M.
    Bhardwaj, C.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S259 - S260
  • [8] New Onset Diabetes After Transplantation (NODAT) - scientific data review
    Zielinska, Katarzyna
    Kukulski, Leszek
    Wrobel, Marta
    Przybylowski, Piotr
    Zielinska, Marta
    Strojek, Krzysztof
    CLINICAL DIABETOLOGY, 2020, 9 (05): : 356 - 366
  • [9] Prevalence and Risk Factors of New-Onset Diabetes After Transplantation (NODAT)
    Zielinska, Katarzyna
    Kukulski, Leszek
    Wrobel, Marta
    Przybylowski, Piotr
    Zakliczynski, Michal
    Strojek, Krzysztof
    ANNALS OF TRANSPLANTATION, 2020, 25 : 1 - 6
  • [10] New Onset Diabetes After Kidney Transplantation [NODAT] Despite the Use of a Steroid-Sparing Regime
    Moutzouris, D.
    Baker, C.
    Kumar, N.
    Willicombe, M.
    Corbett, R.
    Duncan, N.
    Galliford, J.
    McLean, A.
    Taube, D.
    TRANSPLANTATION, 2014, 98 : 524 - 524